Cover Image

Novel Kappa-Opioid Receptor Agonist for the Treatment of Cholestatic Pruritus: Systematic Review

Saved in:

Bibliographic Details
Main Authors:	Adrian Joseph Michel Bailey (Author), Heidi Oi-Yee Li (Author), Mark G Kirchhof (Author)
Format:	Book
Published:	JMIR Publications, 2022-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cholestatic pruritus: a knowledge update
by: Thaís Reginatto Nietsche, et al.
Published: (2022)

Therapeutic Potential of Kappa Opioid Agonists
by: Tyler C. Beck, et al.
Published: (2019)

Itching-like behavior: A common effect of the kappa opioid receptor antagonist 5'-guanidinonaltrindole and the biased kappa opioid receptor agonist 6'-guanidinonaltrindole in mice
by: Alan Cowan, et al.
Published: (2021)

Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands
by: Chiara Sturaro, et al.
Published: (2022)

Analgesic Activity of the Kappa Opioid Receptor Agonist - RU-1205 in Rats / Spasov AA ... [et al.]
by: AA, Spasov, et al.
Published: (2018)

Sex Differences in Kappa Opioid Receptor Agonist Mediated Attenuation of Chemotherapy-Induced Neuropathic Pain in Mice
by: Kelly F. Paton, et al.
Published: (2022)

Evaluation of the abuse potential of difelikefalin, a selective kappa‐opioid receptor agonist, in recreational polydrug users
by: Megan J. Shram, et al.
Published: (2022)

Efficacy of Treatments for Cholestatic Pruritus: A Systemic Review and Meta-analysis
by: Charles Dervout, et al.
Published: (2022)

Agonist-Promoted Phosphorylation and Internalization of the Kappa Opioid Receptor in Mouse Brains: Lack of Connection With Conditioned Place Aversion
by: Chongguang Chen, et al.
Published: (2022)

Distribution, excretion and metabolic pathways of a single parenteral administration of kappa-opioid receptor agonist RU-1205
by: Alexander A. Spasov, et al.
Published: (2021)

Salvinorin A, a kappa-opioid receptor (KOP-r) agonist hallucinogen: Pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders
by: Eduardo eButelman, et al.
Published: (2015)

In Vitro, In Vivo and In Silico Characterization of a Novel Kappa-Opioid Receptor Antagonist
by: Kristina Puls, et al.
Published: (2022)

Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double‐blind, placebo‐controlled trial
by: Eugene R. Viscusi, et al.
Published: (2021)

Models of neuroinflammation for the assessment of kappa-opioid receptor ligands
by: K. Yu. Kalitin, et al.
Published: (2023)

Antinociceptive and Antipruritic Effects of HSK21542, a Peripherally-Restricted Kappa Opioid Receptor Agonist, in Animal Models of Pain and Itch
by: Xin Wang, et al.
Published: (2021)

Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH
by: Samer Al-Dury, et al.
Published: (2018)

Does the kappa opioid receptor system contribute to pain aversion?
by: Catherine M Cahill, et al.
Published: (2014)

The Kappa Opioid Receptor: Candidate Pharmacotherapeutic Target for Multiple Sclerosis
by: Brian Reed, et al.
Published: (2023)

Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implicationsCapsule Summary
by: Sarina Elmariah, MD, PhD, et al.
Published: (2022)

The κ-Opioid Receptor Agonist U50488H Ameliorates Neuropathic Pain Through the Ca2+/CaMKII/CREB Pathway in Rats
by: Zhang XM, et al.
Published: (2022)

Repeated Administration of Norbinaltorphimine Produces Cumulative Kappa Opioid Receptor Inactivation
by: Charles Chavkin, et al.
Published: (2019)

The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies
by: Martin L. Dalefield, et al.
Published: (2022)

An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects
by: Alexander R. French, et al.
Published: (2022)

In vitro and in vivo Pharmacological Activities of 14-O-Phenylpropyloxymorphone, a Potent Mixed Mu/Delta/Kappa-Opioid Receptor Agonist With Reduced Constipation in Mice
by: Roberta Lattanzi, et al.
Published: (2018)

Role for μ-opioid receptor in antidepressant effects of δ-opioid receptor agonist KNT-127
by: Yuki Moriya, et al.
Published: (2023)

Neuraxial opioid-induced pruritus: An update
by: Kamal Kumar, et al.
Published: (2013)

Association of hidradenitis suppurativa and liver disease: A systematic review and meta-analysis
by: Adrian Michel Joseph Bailey, BSc, et al.
Published: (2022)

Sex Differences in the Effects of a Kappa Opioid Receptor Antagonist in the Forced Swim Test
by: Abigail Laman-Maharg, et al.
Published: (2018)

μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges
by: Leah M. Salinsky, et al.
Published: (2023)

Genetic Analysis of Mu and Kappa Opioid Receptor and COMT Enzyme in Cancer Pain Tunisian Patients Under Opioid Treatment
by: Imen CHATTI, et al.
Published: (2017)

Interim opioid agonist treatment for opioid addiction: a systematic review
by: Laura Samsó Jofra, et al.
Published: (2022)

Comparison of Five Benzodiazepine-Receptor Agonists on Buprenorphine-Induced µ-Opioid Receptor Regulation
by: Géraldine Poisnel, et al.
Published: (2009)

The distinct role of kappa opioid receptor in attenuating relapse to morphine/methamphetamine (polydrug) dependence in mice
by: Irna Elina Ridzwan, et al.
Published: (2018)

Editorial: Kappa opioid receptors revealed: Disentangling the pharmacology to open up new therapeutic strategies
by: Wendy Margaret Walwyn, et al.
Published: (2022)

Traumatic Stress-Induced Vulnerability to Addiction: Critical Role of the Dynorphin/Kappa Opioid Receptor System
by: Claire Leconte, et al.
Published: (2022)

Goshajinkigan reduces bortezomib-induced mechanical allodynia in rats: Possible involvement of kappa opioid receptor
by: Hitomi Higuchi, et al.
Published: (2015)

Butorphanol: Effects of a Prototypical Agonist-Antagonist Analgesic on κ-Opioid Receptors
by: Stephen Commiskey, et al.
Published: (2005)

Desmetramadol Is Identified as a G-Protein Biased µ Opioid Receptor Agonist
by: John A. Zebala, et al.
Published: (2020)

Effects of kappa-opioid agonist U-50488 and p38 MAPK inhibitor SB203580 on the spike activity of pyramidal neurons in the basolateral amygdala
by: Konstantin Y. Kalitin, et al.
Published: (2024)

Cardiorenal Effects of Kappa Opioid Peptides During Ontogeny
by: Wei Qi, et al.
Published: (2011)